Minutes of the CAT meeting 21-23 January 2026
Submitted by Anonymous (not verified) on 4 March 2026 - 8:20
Minutes of the CAT meeting 21-23 January 2026
Annual report on the use of the special contribution for orphan medicinal products - 2025
Submitted by Anonymous (not verified) on 3 March 2026 - 16:55
Annual report on the use of the special contribution for orphan medicinal products - 2025
Questions and answers on the use of out-of-specification batches of authorised cell and tissue-based advanced therapy medicinal products
Submitted by Anonymous (not verified) on 3 March 2026 - 16:41
Questions and answers on the use of out-of-specification batches of authorised cell and tissue-based advanced therapy medicinal products
Consolidated 3-year work plan for the clinical domain
Submitted by Anonymous (not verified) on 3 March 2026 - 16:19
Consolidated 3-year work plan for the clinical domain
Scientific advice and protocol assistance adopted during the CHMP meeting 23-26 February 2026
Submitted by Anonymous (not verified) on 3 March 2026 - 16:03
Scientific advice and protocol assistance adopted during the CHMP meeting 23-26 February 2026
Medicines for human use under evaluation
Submitted by Anonymous (not verified) on 3 March 2026 - 15:40
Medicines for human use under evaluation
EMA/PE/0000228283
Submitted by Anonymous (not verified) on 3 March 2026 - 15:36
EMA/PE/0000228283
Human medicines European public assessment report (EPAR): Afqlir, aflibercept, Date of authorisation: 13/11/2024, Revision: 6, Status: Authorised
Submitted by Anonymous (not verified) on 3 March 2026 - 15:35
Human medicines European public assessment report (EPAR): Afqlir, aflibercept, Date of authorisation: 13/11/2024, Revision: 6, Status: Authorised
Ifosfamide
Submitted by Anonymous (not verified) on 3 March 2026 - 15:22
Ifosfamide
Cyclophosphamide
Submitted by Anonymous (not verified) on 3 March 2026 - 15:21
Cyclophosphamide